These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 34354863)

  • 1. A novel five-gene score to predict complete pathological response to neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer.
    Oshi M; Gandhi S; Angarita FA; Kim TH; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
    Am J Cancer Res; 2021; 11(7):3611-3627. PubMed ID: 34354863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer.
    Sato T; Oshi M; Huang JL; Chida K; Roy AM; Endo I; Takabe K
    Breast Cancer Res Treat; 2024 Nov; 208(2):415-427. PubMed ID: 39017815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer.
    Sato T; Oshi M; Huang JL; Chida K; Roy AM; Endo I; Takabe K
    Res Sq; 2024 Mar; ():. PubMed ID: 38585981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Expression of NRF2 Is Associated with Increased Tumor-Infiltrating Lymphocytes and Cancer Immunity in ER-Positive/HER2-Negative Breast Cancer.
    Oshi M; Angarita FA; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33371179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Oshi M; Asaoka M; Tokumaru Y; Angarita FA; Yan L; Matsuyama R; Zsiros E; Ishikawa T; Endo I; Takabe K
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33086518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Oshi M; Angarita FA; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2- Breast Cancer.
    Oshi M; Takahashi H; Tokumaru Y; Yan L; Rashid OM; Nagahashi M; Matsuyama R; Endo I; Takabe K
    Cells; 2020 Jul; 9(7):. PubMed ID: 32650578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High miR-99b expression is associated with cell proliferation and worse patient outcomes in breast cancer.
    Oshi M; Tokumaru Y; Benesch MG; Sugito N; Wu R; Yan L; Yamada A; Chishima T; Ishikawa T; Endo I; Takabe K
    Am J Cancer Res; 2022; 12(10):4840-4852. PubMed ID: 36381329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High expression of polo-like kinase 1 is associated with TP53 inactivation, DNA repair deficiency, and worse prognosis in ER positive Her2 negative breast cancer.
    Takeshita T; Asaoka M; Katsuta E; Photiadis SJ; Narayanan S; Yan L; Takabe K
    Am J Transl Res; 2019; 11(10):6507-6521. PubMed ID: 31737202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MELK expression in breast cancer is associated with infiltration of immune cell and pathological compete response (pCR) after neoadjuvant chemotherapy.
    Oshi M; Gandhi S; Huyser MR; Tokumaru Y; Yan L; Yamada A; Matsuyama R; Endo I; Takabe K
    Am J Cancer Res; 2021; 11(9):4421-4437. PubMed ID: 34659896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer.
    Oshi M; Gandhi S; Yan L; Tokumaru Y; Wu R; Yamada A; Matsuyama R; Endo I; Takabe K
    Breast Cancer Res Treat; 2022 Jul; 194(2):231-241. PubMed ID: 35639264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral Tumor Infiltrating Lymphocytes (TILs) are Associated With Cell Proliferation and Better Survival But Not Always With Chemotherapy Response in Breast Cancer.
    Wu R; Oshi M; Asaoka M; Yan L; Benesch MGK; Khoury T; Nagahashi M; Miyoshi Y; Endo I; Ishikawa T; Takabe K
    Ann Surg; 2023 Oct; 278(4):587-597. PubMed ID: 37318852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerated glycolysis in tumor microenvironment is associated with worse survival in triple-negative but not consistently with ER+/HER2- breast cancer.
    Oshi M; Roy AM; Yan L; Sasamoto M; Tokumaru Y; Wu R; Yamada A; Yamamoto S; Chishima T; Narui K; Endo I; Takabe K
    Am J Cancer Res; 2023; 13(7):3041-3054. PubMed ID: 37559984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced Thermogenesis in Triple-Negative Breast Cancer Is Associated with Pro-Tumor Immune Microenvironment.
    Gandhi S; Oshi M; Murthy V; Repasky EA; Takabe K
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34071012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a novel BRCAness score that predicts response to PARP inhibitors.
    Oshi M; Gandhi S; Wu R; Asaoka M; Yan L; Yamada A; Yamamoto S; Narui K; Chishima T; Ishikawa T; Endo I; Takabe K
    Biomark Res; 2022 Nov; 10(1):80. PubMed ID: 36371386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients.
    Risi E; Grilli A; Migliaccio I; Biagioni C; McCartney A; Guarducci C; Bonechi M; Benelli M; Vitale S; Biganzoli L; Bicciato S; Di Leo A; Malorni L
    Breast Cancer Res Treat; 2018 Jul; 170(2):329-341. PubMed ID: 29564743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
    Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
    Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Th2 cell infiltrations predict neoadjuvant chemotherapy response of estrogen receptor-positive breast cancer.
    Le L; Tokumaru Y; Oshi M; Asaoka M; Yan L; Endo I; Ishikawa T; Futamura M; Yoshida K; Takabe K
    Gland Surg; 2021 Jan; 10(1):154-165. PubMed ID: 33633972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.
    Petruolo OA; Pilewskie M; Patil S; Barrio AV; Stempel M; Wen HY; Morrow M
    Ann Surg Oncol; 2017 Sep; 24(9):2556-2562. PubMed ID: 28560596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.